H.C. Wainwright analyst Robert Burns upgraded Zymeworks (ZYME) to Buy from Neutral with a price target of $26, up from $13. The firm sees the Phase 1 results for ZW191 at the upcoming Triple meeting later this month and top-line data release for the Phase 3 HERIZON-GEA-01 trial by end-2025 as catalysts for the shares. It upgraded Zymeworks following recent developments the company’s pipeline.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Presents Promising Phase 1 Data for ZW191 at International Conference
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Zymeworks initiated with a Buy at B. Riley
- Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements
- Zymeworks appoints Adam Schayowitz as Acting Chief Development Officer